Med Ed 101

JULY 30, 2023

After my recent post on my top 5 medication/vitamin interactions, I received the request to cover medications that deplete vitamins and minerals. I loved this idea because it is an important consideration in clinical practice! Keep in mind that these often show up on pharmacology and board exams as well! Without further ado, here are […] The post Medications That Deplete Vitamins And Minerals – Top 10 appeared first on Med Ed 101.

98

98

EMCrit Project

JULY 30, 2023

Lower dose peripheral infusion for sick pulmonary embolism patients EMCrit Project by Scott Weingart, MD FCCM.

90

90

Pharmacy Joe

JULY 30, 2023

In this episode, I’ll discuss the management of suspected propofol dependence with phenobarbital in an adult patient with COVID-19. Episode 839: A Rare Case of Propofol Dependence and How it Was Managed Subscribe on iTunes , Android , or Stitcher There is limited published information on propofol withdrawal syndrome. Authors recently published a case report of their experience treating a patient with suspected propofol dependence with phenobarbital in the American Journal of Health-System Pharma

Inpatient 52

Inpatient 52

Pharmaceutical Business Review

JULY 30, 2023

RiVive is designed to provide access to naloxone without a prescription and is available as 3 mg naloxone hydrochloride nasal spray. This is the second over-the-counter product with the first nonprescription nasal spray approved in March 2023. Naloxone rapidly reverses the effects of opioid overdose and is considered as the standard treatment for opioid overdose.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Patent Watch

JULY 30, 2023

Annual Drug Patent Expirations for QTERNMET+XR Qternmet Xr is a drug marketed by Astrazeneca Ab and is included in one NDA. There are seven patents protecting this drug. Drug patent… The post New patent expiration for Astrazeneca Ab drug QTERNMET XR appeared first on DrugPatentWatch - Make Better Decisions.

52

52

PharmaState Academy

JULY 30, 2023

Note: You can participate only 1 time. Participation by using another name & email id will lead to disqualification. The winner will be announced after profile verification. Once you're a winner, you will not be considered for the prizes for another two months. Note: You can participate only 1 time. Participation by using another name & email id will lead to disqualification.

52

52

RX Note

JULY 30, 2023

Introduction One common question that we encountered at work is if this drug has any adverse effects? Or rather, as a pharmacist, we should warn the patients on the potential adverse effects of a newly started drugs (especially those very common or needs urgent medical attention). NOTE: Clinical decision is often a judgement between potential benefits and harms of a treatment.

Adverse Reactions 52

Adverse Reactions Patient Counseling Medical Records Documentation 52

Drug Patent Watch

JULY 30, 2023

Obeticholic acid is the generic ingredient in one branded drug marketed by Intercept Pharms Inc and is included in one NDA. There are ten patents protecting this compound. Drug patent… The post New tentative approval for Optimus Pharma drug obeticholic acid appeared first on DrugPatentWatch - Make Better Decisions.

Compounding 52

Compounding 52

RX Note

JULY 30, 2023

Introduction Pharmacists often face situations where they need to make quick, informed decisions that may impact patient safety. While many clinical decisions are based on facts, there are many "less straightforward" scenarios that require analytical and critical thinking skills due to their complexity. Multiple Priorities During your first night shift, there are few things happening at the same time.

Hospitals 40

Hospitals Dosage Communication 40

Drug Patent Watch

JULY 30, 2023

Annual Drug Patent Expirations for KOMBIGLYZE+XR Kombiglyze Xr is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are three… The post New patent expiration for Astrazeneca Ab drug KOMBIGLYZE XR appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

PharmExec

JULY 30, 2023

Webinar Date/Time: Tue, Sep 12, 2023 10:00 AM EDT | 9:00 AM CT | 3:00 PM BST | 4:00 PM CEST

HIPAA 52

HIPAA 52

Drug Patent Watch

JULY 30, 2023

Annual Drug Patent Expirations for QTERN Qtern is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are nine patents… The post New patent expiration for Astrazeneca Ab drug QTERN appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharmaceutical Technology

JULY 30, 2023

Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

40

40

Drug Patent Watch

JULY 30, 2023

DEXILANT SOLUTAB (dexlansoprazole) Takeda pharms usa Patent: 6,664,276 Expiration: Jul 30, 2023 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact… The post Drug Patent Expirations for the Week of July 30, 2023 appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharmaceutical Technology

JULY 30, 2023

Pelabresib is a small molecule commercialized by MorphoSys, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF).

40

40

pharmaphorum

JULY 30, 2023

FDA rejects Citius' revived IL-2 therapy for lymphoma Phil.

62

62

Pharmaceutical Technology

JULY 30, 2023

Gedeptin is a gene therapy commercialized by GeoVax Labs, with a leading Phase II program in Recurrent Head And Neck Cancer Squamous Cell Carcinoma.

40

40

Drug Patent Watch

JULY 30, 2023

This chart shows the drugs with the most patents in Croatia. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Croatia? appeared first on DrugPatentWatch - Make Better Decisions.

52

52

Pharmaceutical Technology

JULY 30, 2023

Gedeptin is a gene therapy commercialized by GeoVax Labs, with a leading Phase II program in Recurrent Head And Neck Cancer Squamous Cell Carcinoma.

40

40

Pharmaceutical Technology

JULY 30, 2023

Vamorolone is a small molecule commercialized by Catalyst Pharmaceuticals, with a leading Pre-Registration program in Duchenne Muscular Dystrophy.

40

40

Pharmaceutical Technology

JULY 30, 2023

Nirogacestat hydrobromide is a small molecule commercialized by SpringWorks Therapeutics, with a leading Pre-Registration program in Benign Tumor.

40

40

Pharmaceutical Technology

JULY 30, 2023

Vamorolone is a small molecule commercialized by Catalyst Pharmaceuticals, with a leading Pre-Registration program in Duchenne Muscular Dystrophy.

40

40

Pharmaceutical Technology

JULY 30, 2023

Nirogacestat hydrobromide is a small molecule commercialized by SpringWorks Therapeutics, with a leading Pre-Registration program in Benign Tumor.

40

40

Pharmaceutical Technology

JULY 30, 2023

FPI-1434 is a monoclonal antibody conjugated commercialized by Fusion Pharmaceuticals, with a leading Phase II program in Endometrial Cancer.

40

40

Pharmaceutical Technology

JULY 30, 2023

PF-06480605 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Crohn's Disease (Regional Enteritis).

40

40

Pharmaceutical Technology

JULY 30, 2023

PF-06480605 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Crohn's Disease (Regional Enteritis).

40

40

Pharmaceutical Technology

JULY 30, 2023

CAP-1002 is a cell therapy commercialized by Nippon Shinyaku, with a leading Phase III program in Duchenne Muscular Dystrophy.

40

40

Pharmaceutical Technology

JULY 30, 2023

CAP-1002 is a cell therapy commercialized by Nippon Shinyaku, with a leading Phase III program in Duchenne Muscular Dystrophy.

40

40

Pharmaceutical Technology

JULY 30, 2023

BNT-321 is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JULY 30, 2023

BNT-321 is a monoclonal antibody commercialized by BioNTech, with a leading Phase II program in Metastatic Colorectal Cancer.

40

40

Pharmaceutical Technology

JULY 30, 2023

Resiniferatoxin is a small molecule commercialized by Shionogi, with a leading Phase III program in Osteoarthritis Pain.

40

40

Pharmaceutical Technology

JULY 30, 2023

BGB-3245 is a small molecule commercialized by SpringWorks Therapeutics, with a leading Phase II program in Solid Tumor.

40

40

Pharmaceutical Technology

JULY 30, 2023

Resiniferatoxin is a small molecule commercialized by Shionogi, with a leading Phase III program in Osteoarthritis Pain.

40

40